Cite
HARVARD Citation
Zheng, H. et al. (2021). A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia. American journal of hematology. 96 (2), pp. E46-E50. [Online].